Strados Labs Announces Study Evaluating Remote Lung Sound Monitoring to Predict COPD Exacerbations

The SHORE study, in collaboration with Jefferson Health, will assess the feasibility of home-based, continuous monitoring of cough and lung sounds including wheeze and rhonchi following COPD exacerbations.

Jan. 28, 2026 at 8:39am

Got story updates? Submit your updates here. ›

Strados Labs, a medical technology company, has announced an observational research study evaluating remote lung sound monitoring in patients with chronic obstructive pulmonary disease (COPD) using its FDA 510(k) cleared RESP ® Biosensor. The study, titled SL-RS-SHORE (NCT06544928), will take place at Jefferson Einstein Philadelphia Hospital and affiliated outpatient pulmonary clinics, with plans to enroll up to 20 adults with COPD following a recent exacerbation.

Why it matters

COPD exacerbations are a leading cause of hospitalization and readmission in the United States, yet clinicians have limited tools to assess respiratory status once patients return home. This study aims to evaluate whether continuous, passive monitoring of cough and lung sounds using a stethoscope-based wearable device can help extend respiratory assessments into the home environment with the goal of preventing unnecessary readmissions.

The details

The observational study will follow patients for 90 days after hospital discharge or post-exacerbation outpatient follow-up. The primary objective is to assess the feasibility of remote lung sound monitoring, including patient adherence, compliance, and retention using the Strados Labs ® RESP ® Biosensor. Secondary and exploratory objectives will explore associations between data captured by the RESP ® Biosensor, such as cough frequency, wheeze, rhonchi, respiratory rate and sleep/wake, and standard measures of COPD symptom burden, including the EXACT ® questionnaire, pulse oximetry, and spirometry.

  • Enrollment started in January 2026.
  • The study is expected to run for approximately 12 months, including start-up, enrollment, and data analysis phases.

The players

Strados Labs

A medical technology company focused on improving the lives of patients with respiratory diseases through innovative technology.

Jefferson Health

A not-for-profit health care system that serves patients through millions of encounters each year at 32 hospital campuses and more than 700 outpatient and urgent care locations throughout the region.

Sadia Benzaquen, MD

The Principal Investigator at Jefferson Health and the Chair of Pulmonary, Critical Care, and Sleep Medicine at Jefferson Einstein Philadelphia Hospital.

Nick Delmonico

The CEO and Cofounder of Strados Labs.

Got photos? Submit your photos here. ›

What they’re saying

“Home monitoring has already shown promise in improving self-management and detecting exacerbations. This study will help provide additional information to determine if this technology could offer a simpler and more continuous way to keep patients and providers informed in real-time.”

— Sadia Benzaquen, MD, Principal Investigator at Jefferson Health (Strados Labs)

“COPD has long been an important focus for us at Strados, in part because it remains such a difficult disease to manage effectively outside the clinic. After discharge, clinicians have limited visibility into how patients are really doing day to day. We're excited to build on our previous COPD research and further explore how continuous monitoring of cough and lung sounds may provide valuable information during this high-risk period for so many patients.”

— Nick Delmonico, CEO & Cofounder at Strados Labs (Strados Labs)

What’s next

Findings from the SHORE study are anticipated to inform future studies evaluating remote lung sound monitoring strategies in COPD and other chronic respiratory diseases.

The takeaway

This study aims to leverage wearable technology to provide clinicians with continuous, real-time insights into the respiratory status of COPD patients after they are discharged from the hospital, with the goal of preventing unnecessary readmissions and improving overall disease management.